Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22642216 | 0.97 | AR (0.70) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL26115570 | 0.95 | AR (0.69) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL15506537 | 0.95 | AR (0.71) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL17940985 | 0.93 | AR (0.64) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL26103724 | 0.93 | AR (0.64) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL26102143 | 0.93 | AR (0.64) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL17954406 | 0.92 | AR (0.66) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL17941040 | 0.90 | AR (0.67) | ARPGRABCG2HDAC3HDAC1 | |
| SCHEMBL19599671 | 0.90 | AR (0.71) | ARPGRABCG2HDAC1 | |
| SCHEMBL31476807 | 0.89 | AR (0.66) | ARPGRABCG2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081091-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | BRDT, NFKBIA, SSB | AR 4330/4885PGR 3097/4885ABCG2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.